An optimized formulation of capsules containing Lansoprazole enteric-coated pellets using D-Optimal design with a polynomial statistical model were prepared by using Eudragit®L100 as an enteric coated polymer to provide resistance to simulated gastric acid dissolution in buffer media. D-Optimal experimental design was used to determine the optimal level for three coating layers that were applied to formulate the enteric-coated pellets including a drug loading layer, a sub-coating, and an outer enteric coating. Dissolution studies were performed on the prepared Lansoprazole capsules. Less than 5 percent of Lansoprazole was released in 60 minutes in an acidic dissolution medium (pH 1.2) and greater than 90 percent of active ingredient was released in the next 60 minutes in a buffer dissolution medium (pH 6.8). The Lansoprazole capsules were stable with no observable change in physico-chemical properties in accelerated and normal storage conditions for 6 and 18 months, respectively. The pharmacokinetic parameters C max , T max , AUC 0−t , and AUC 0−∞ were determined after administration of the D-Optimal design optimized capsules of LPZ to healthy beagle dogs and were statistically compared to Gastevin® capsules as a reference (KRKA, Slovenia) using the non-compartmental method with the aid of WinNonlin 5.2 software. The analysis of variance showed that the two formulations did not demonstrate bioequivalence using a 90% confi- dence interval range (80% -120%) of C max , AUC 0−t , and AUC 0−∞ . No significant difference in T max was found at the 0.95 significance level using the Wilcoxon signed-rank test. D-Optimal Experimental Design provided definitive direction for an optimal formulation of capsules containing enteric-coated pellets of lansoprazole loaded within the coating of pellets that provided similar bioequivalence to Gastevin.
Introduction
Lansoprazole (LPZ), a proton pump inhibitor, is a lipophilic weak base with pKa values of 4.15 and 1.33, where the N-H proton in the benzimidazole ring is responsible for the acidity of the molecule (pKa 8.84). LPZ reduces gastric acidity, an important factor in healing acid-related disorders such as gastric ulcers, duodenal ulcers, and reflux esophagitis. It is used to treat gastro-oeesophageal reflux, ulcers, acid-related dyspepsia, and as an adjuvant in the eradication of Helicobacter pylori. It tends to relieve heartburn more effectively than omeprazole at therapeutic dosages [1] . However, degradation and the low water solubility of the lansoprazole lead to a reduction in its bioavailability when administrated orally. The degradation of lansoprazole in acidic medium is strongly pH-dependent. The half-life of the LPZ in different pH's varies dramatically:
only 15 minutes at pH 2.0; 18 hours at pH 6.0, and up to 34 hours at pH 8.0 [2] .
The use of alkaline salts such as sodium carbonate, dibasic sodium phosphate, magnesium oxide, and magnesium carbonate have been indicated to increase the stability of LPZ, in which dibasic sodium phosphate is suggested as the most efficient stabilizer for protecting the drug against degradation [3] . Furthermore, an enteric-coated formulation is essential to protect the drug from the acidic environment of stomach.
The formulation challenge concerning a LPZ oral dosage form is the drug's poor water solubility producing poor absorption that results in low bioavailability. Efforts to improve the solubility of LPZ by utilizing a liquid solid technique, a solid dispersion system, and by spray drying were reported. The liquid solid technique use of Tween 80 as a carrier to increase wetting of the surface area available for enhanced LPZ's dissolution rate [4] . A solid dispersion system composed of LPZ, a surfactant such as Tween 80, polyoxy 60 hydrogenated castor oil derivative (HCO-60), and PEG-8 caprylic/capric glycerides (Labrasol) presented the possibility of being a good method to improve the bioavailability of LPZ [5] . Additionally, utilizing the amorphous crystalline state of LPZ coupled with the presence of a hydrogen bond between LPZ and PVP K30 in a solid dispersion system markedly enhanced the dissolution rate more than 80%
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of drug within 30 minutes [6] .
Pellets, multi-unit dosage forms, are easy to swallow while maintaining the merits of multiple units, bring about several therapeutic advantages including delayed of drug release, division of dose strength, and rapid distribution in the gastrointestinal tract when administered orally. In addition, a higher degree of flexibility in design and development during delivery of incompatible bioactive agents is also another pharmaceutical benefit of pellets [7] .
The use of Eudragit L30D-55 as an enteric-coating polymer to formulate LPZ enteric-coated pellets, while at the same time using HPMC E5 for its role as a polymer in layering and sub-coating membrane for core pellets, the drug release from these enteric-coated pellets in 0.1 N HCl and in phosphate buffer (pH 6.8) media was 0.71% and 97.87%, respectively. The formulation was stable for 3 months at 40˚C ± 2˚C/75% RH ± 5% [8] . In another study, three coating materials were used with manitol for the first layer, PVP K30 for the second layer, and HPMCP for the final layer in capsules of LPZ-modified release pellets to investigate controlled release properties of hypromellose phthalate by avoiding the gastric release of LPZ. The results showed that the drug release from capsules in an acidic medium (pH 1.2) were 0.8% to 1.2% and up to 94.9% in a buffer medium (pH 6.8) over 60 minutes [9] . Recently, LPZ enteric-coated pellets have been prepared using low substituted-HPC as a polymer for drug layering and seal coating, and Eudragit L30D-55 as the enteric-coating polymer for the dosage form. The optimized LPZ formulations' reported release from enteric-coated pellets in an acidic medium was 3.6%, and the drug release in pH 6.8 phosphate buffer was 86% over 60 minutes. The capsules containing the LPZ pellets showed a desirable drug release in acid and buffer mediums during the stability testing period (3 months at 40˚C/75% RH and 25˚C/60% RH) [10] .
Currently, applying D-Optimal experimental design to optimize drug release from enteric-coated pellets where the coating layers are impregnated with drug for drug delivery has not been performed. The main purpose of this study was to use D-Optimal experimental design utilizing Modde 5.0 software to formulate and develop a stable, delayed release pellet formulation of LPZ with LPZ incorporated in the pellet coating, which satisfies the requirements of USP XXXV on drug dissolution in the gastrointestinal tract [11] . Then compare LPZ in vitro dissolution and in vivo bioavailability of the resultant designed LPZ formualtion to the reference product on the market (Gastevin® capsules from Slovenia).
Materials and Methods

Chemicals
LPZ was purchased from Jai Radhe Sales (India). Eudragit®L100 was obtained as a free sample from Evonik (Germany). Lutrol F127 was provided by BASF USA (United States of America). PVA (polyvinyl alcohol) was received from Kuraray Asia Pacific Pte Ltd (Singapore). HPMC (hydroxy-propyl-methyl cellulose) E15 was obtained from Zhejiang Zhongbao (China). TEC (triethyl citrate) was purchased from Cognis (Germany). PEG (polyethylene glycol) 6000 was procured from Sino-Japan Chemical Co Ltd (Taiwan). Titanium dioxide (Titan Dioxide) was obtained from Cosmo (Republic of Korea). Sugar spheres were purchased from Colorcon Asia Pacific Pte Ltd (Singapore). Methanol (MeOH), acetonitrile, triethylamine and tert-butyl methyl ether were HPLC grade and purchased from Merck (Germany) and all other ingredients used were of analytical grade.
Animals and study products: The in vivo study utilized six healthy beagle dogs (between 10 kg and 12 kg in weight). The study protocol was approved by the ethics committee of medicine and pharmacy research at Military Medical University (Hanoi, Vietnam).
Test product: Thirty mg of enteric-coated LPZ loaded pellets in capsules of the optimized formulation were prepared. Reference product: Gastevin® 30 mg capsules were purchased from KRKA (Slovenia) containing LPZ enteric-coated pellets, manufacture date: 02/2013, expiration date: 02/2016.
Preparation of LPZ Enteric-Coated Pellets
Drug loading and sub-coating: The adoption of sugar spheres as the core to load a polymer coating of drug onto to formulate the LPZ pellets, and the application of the sub-coating immediately over the drug loaded core pellets after drug loading were performed as follows. The drug coating dispersion and sub coating dispersion with LPZ and other ingredients in each formulation (Table 1) Three batches of 3300 capsules (with each capsule containing 30 mg LPZ, equivalent to 1000 g pellets per batch) of the optimal formulation were prepared to evaluate the stability of capsules containing LPZ enteric-coated pellets. The LPZ enteric-coated pellets were filled in hard gelatin capsules using a HanYang HFC45 capsule filling machine (Republic of Korea). The hard gelatin capsules were packed in aluminum blisters using an Uhlmann CP250 blister packing machine (Vietnam).
Drug Content
Spectrophotometric method: Drug content assays were performed in triplicate.
An amount of coated pellets equivalent to 50 mg of LPZ was weighed and put into a dry 50-mL volumetric flask. Methanol (MeOH) was used to dissolve the drug under sonication for 15 minutes. Then the samples were centrifuged at 5000 rpm for 10 minutes to assure clarity of the sample for assay. Supernatant 
In vitro Dissolution Studies
The release of LPZ from enteric-coated pellets in the simulated environment of the gastrointestinal tract was determined using the USP XXXV dissolution apparatus II (Erweka equipment with paddle at 37˚C ± 0.5˚C and 75 rpm, Germany).
Acid stage (pH 1.2): LPZ release from pellets having the equivalent of 30-mg LPZ in vessels containing 500 mL of 0.1 N HCl dissolution media was determined after 1 hour. The quantity of drug in the pellets was assayed by HPLC or spectrophotometric method as follows:
HPLC method: The medium was drained without losing the pellets; HPLC method outlined above was used for determination of remaining drug in pellets.
Spectrophotometric method: Having withdrawn a 25-mL aliquot and filtering it, the amount of drug dissolved was determined by measuring UV absorption at the wavelength of maximum absorbance at 306 nm.
Buffer stage (pH 6. Comparison of the two drug dissolution profiles (reference versus test formulations) was performed using the similarity factor f 2 which is calculated as follows (Equation (1)) [13] :
1 50 log 1 100
where R t and T t are the percentages of drug release at time t of the reference and the test formulations, respectively; n is the number of time points. If f 2 is equal to or more than 50, the two drug release profiles will be considered to be similar.
Stability Studies
Stability studies were carried out using 3300 capsules from batches of the optimal formulation. The optimal formulation batches were stored at various temper- 
In vivo Studies
Drug administration and sample collection: This study was based on a single-dose, randomized, two-period crossover design. Six healthy beagle dogs were fed standardized meals for 3 days before inclusion into the study. The number of dogs in the study was determined from a pilot study of two doses and variance of data obtained. Each drug was taken after an overnight fast. In the morning of phase I, three randomly chosen dogs were given a single dose of reference product and three other dogs were given a single dose of test product with 100 mL of analysis of variance for crossover design and calculating standard 90% confidence intervals of the ratio test/reference. The products were considered bioequivalent if the difference between two compared parameters was found statistically insignificant (P ≥ 0.05) and 90% confidence intervals for these parameters fell within 80% -120%.
Results
Formulation of LPZ Enteric-Coated Pellets
Effects of the independent variables on the response variables: LPZ entericcoated pellets were prepared by using Eudragit®L100 as the enteric coating polymer. The independent variables and the range of levels incorporated in to the test formulations are shown in Table 2 . The amount of titanium dioxide was A. Q. Luong et al. Optimization of the formulation of LPZ enteric-coated pellets: Based on the experimental dissolution data, the range of optimal conditions for dependent variables are as follows: the percentages of drug released in acid pH 1.2 medium (0% ≤ Y1 ≤ 10%), and the percentages of drug released in buffer pH 6.8 medium (80% ≤ Y2 ≤ 100%) were identified. Running In Form 3.1 optimization software program, the optimal formulation of enteric coating was extrapolated and shown in Table 4 with the predicted results of their dissolution in acid pH 1.2 medium and buffer pH 6.8 dissolution medium being 4.07% and 90.87%, respectively.
The optimal formulation of enteric coating was prepared at the batch size of 150 g (n = 3) using Diosna spray coater (Germany). The enteric membrane was coated on the subcoating core pellets containing LPZ. The physico-chemical properties of enteric-coated pellets for optimal formulation were evaluated and shown in Table 5 . The obtained results show that the optimal enteric-coated pellets had good flowability (flow rate = 11.8 g/s), and suitable particle size dis-tribution for filling in hard gelatin capsules (0.85 -1.2 mm). The assayed content of drug in the pellets was approximately 8%. The moisture, friability, and bulk density of enteric-coated pellets were in an acceptable range.
The dissolution profiles of optimal formulation pellets were the same as that of Gastevin® 30 mg with f 2 equal to 56.62 (Figure 3 ). Both the optimized test formulation and Gastevin® 30 mg completely released LPZ over 60 minutes in pH 6.8 buffer solution (after testing its acid-resistance capability in pH 1.2 acidic solution for 60 minutes). The gastric resistance of both formulations was below 5% (3.35% for the test formulation, 3.61% for the reference). The dissolution results of the drug release profile from prepared LPZ enteric-coated pellets satisfied the requirements of USP XXXV on drug dissolution in in vitro gastrointestinal tract. 
Optimal formulation Gastevin
The scanning electron microscopy (SEM) of the optimal formulation shows that prepared enteric-coated pellets have a good coating with three individual layers including a drug loading, a subcoating, and an enteric coating (Figure 4 ).
The thickness of each layer was estimated as 50 -80 µm for drug loading and enteric coating, and 10 -20 µm for subcoating. The layers are effective in controlling the release of LPZ in acidic and buffer dissolution media.
Stability studies: Triple batches of 3300 capsules containing the optimal formulation of LPZ enteric-coated pellets were prepared by the same method. The results of dissolution and drug content from the stability study in accelerated and room conditions are summarized in Table 6 . The results reveal that the prepared capsules containing LPZ enteric-coated pellets were stable for 18 months at room conditions and 6 months in accelerated conditions.
In Vivo Study of Capsules Containing LPZ Enteric-Coated Pellets
The mean concentration-time profiles of the LPZ 30-mg test and reference capsules are depicted in Figure 5 . The pharmacokinetic parameters for both formulations are shown in Table 7 . For bioequivalence evaluation, C max , AUC 0−t , and AUC 0−∞ were considered as primary variables for statistical analysis. Various statistical models were applied to the pharmacokinetic parameters per FDA guidelines [14] . The statistical significant differences in the pharmacokinetic parameters between two products were analyzed by ANOVA (analysis of variance) using WinNonlin 5.2 software. The results of the statistical analysis for C max , AUC 0−t , and AUC 0−∞ are shown in Table 8 . In addition, T max was analyzed by non-parametric statistical hypothesis test (Wilcoxon signed-rank test with the results in Table 9 ). Table 7 . Pharmacokinetic parameters of the two products of LPZ 30-mg capsules.
Animal no. The pharmacokinetic data were transformed into natural logarithm (Ln); DF = degrees of freedom; SS = sum of squares; MS = mean square. significance level, ANOVA did not show any significant differences between the two products on all effects. For example, the effects of sequence on C max , the observed P value was 0.728 while the P value was 0.110 for the influence of study subjects on C max . In terms of treatment, no significant differences were seen, (the observed P value was 0.463) and the period effects with the observed P value were 0.579.
For T max , the sum of the ranks of the scores with positive and negative values were 6.5 and 8.5, respectively. Therefore, the smaller sum was 6.5 and the number of differences was 5. Using the differences between the two products on the effects of sequence on AUC 0−t , (P value = 0.557), the effects of subject (P value = 0.129), and the effects of treatment (P value = 0.186). However, there was a statistically significant difference between the test and reference products on period effects (P value < 0.05). The same results were obtained for AUC 0−∞ .
To evaluate the bioavailability of prepared LPZ 30-mg enteric capsules, the in vivo study was conducted based on a single-dose, randomized, two-period crossover design per FDA guidelines. The mean concentration-time profiles of the LPZ 30-mg test and reference capsules showed their delayed-release characteristics in gastrointestinal tract on experimental dogs. With the obtained values of C max , AUC 0−t , and AUC 0−∞ by utilizing the noncompartmental method, the lack of bioequivalence outcome was given between the test and reference products whereas T max of both formulations was equivalent. Although the in vitro dissolution profiles of the two products were similar with f 2 value at 56.62, but the obtained in vivo results were not equivalent which might be caused by the low f 2 and the small number of subjects in the in vivo study. The pharmacokinetic parameters of the two compared capsules were appropriate to the results of previous research [15] [16] . However, due to being limited to using healthy beagle dogs as experimental subjects for the in vivo study and without the option for human subjects might have affected the in vivo bioequivalence assessment.
Discussion and Summary
LPZ is characterized by low solubility and low stability. In this study, the drug layering method was selected to prepare the core pellets containing LPZ. The results also show that the solubility and stability of LPZ increased considerably by layering and including alkaline salts, similarly seen in previous research [10] [17] [18] . These studies loaded the drug in the core pellet and reported that 8 percent loading gave the best release profile from the composition of the drug loaded pellets. In the optimized formulation of this study HPMC E15 and PVA were used as a binder, and dibasic sodium phosphate was used as stabilizer for protecting the drug against degradation. Lutrol F127 is a block copolymer referred to as Poloxamer 407, and was used as a solubilizer for LPZ. Sugar spheres were used as an inert pellet core for loading the drug and other ingredients onto.
Due to the strong degradation of LPZ in highly acidic environments, the enteric coating was applied on the LPZ pellets after drug loading and subcoating. Eudragit®L100 was used as enteric coating polymer in the composition of enteric-coated pellets. However, because of Eudragit®L100's acidity, it is necessary to protect the drug inside the LPZ core pellets from the acidic impact of Eudragit® L100. For this reason, the subcoating was applied onto the LPZ core pellets. PVA was selected as a water-soluble polymer and PEG 6000 also was used as plasticizer. In addition, Lutrol F127 was continually used in formulation of the subcoating because of its anti-humidity effects [19] . All ingredients of layering and subcoating were compatible with LPZ.
As is shown in many earlier studies, some enteric polymers and aqueous dispersions such as HPMCP, HPMCAS, Eudragit®L30D-55, Acrylcoat®L30D have been used for coating derivatives of benzimidazoles [8] [18] [20] [21] . LPZ release from enteric coated pellets were found to be adequately improved by adjusting the amounts of TEC, talc and weight gain of pellets by the coating material [20] [21] . Therefore, these formulation parameters were used in the DOptimal experimental design at the independent variables to optimize the formulation. Release of LPZ from the optimized pellets occurred at the optimal loading of LPZ which was 8.45 which was similar to previous studies [20] [21] . A simple layering coating was applied to nonpareil pellets with LPZ provided good release of LPZ, in this study an optimized coating layer with LPZ was applied around sugar spheres to provide optimal drug release from the final optimized formulation [20] . In this study, Eudragit ® L100 was dissolved into a mixture of D-Optimal was chosen as the approach to create the experimental design for the study as it uses a simpler model in its design, which aims to minimize the variance of factor-effect estimates to create test formulations to study to obtain an optimized formulation. Other experimental design methods such as I-Optimal are available and provide better prediction performance with their experimental designs as it aims to minimize the average variance of prediction over the region of experimentation [22] . The selection criteria of an experimental design approach depends on the approach to variances of the response surface estimators that is preferred: integral/average variance approach. However, D-Optimal is easier to operate and provides nearly as desirable an outcome in its experimental design.
The pharmacokinetic parameters C max , T max , AUC 0−t , and AUC 0−∞ were determined for the D-Optimal design optimized capsules of LPZ given to healthy beagle dogs and were statistically compared to Gastevin® capsules as a reference (KRKA, Slovenia) using the non-compartmental method with the aid of WinNonlin 5.2 software. The analysis of variance showed that the two formulations did not demonstrate bioequivalence using a 90% confidence interval range (80 -120%) for C max , AUC 0−t , and AUC 0−∞ . However, no significant difference in T max was found at the 0.95 significance level using the Wilcoxon signed-rank test.
The prepared capsules containing LPZ enteric-coated pellets were stable for 18 months at room conditions and 6 months in accelerated conditions. The use of D-Optimal to experimentally design an optimal dosage form was quite satisfactory. The experimental design yielded an optimal formulation that produced similar bioequivalence to the commercially available reference lansoprazole product. The stability study results have important significance for this formulation in zone IV, which includes Vietnam as well as other countries in South-East Asia.
